Delius Pharma posts 672.50% YoY Q1 growth, driven by antibiotics sales, API imports from China, new leadership, and Rs 70 crore plant investment; targets Rs 350 crore turnover by FY25-end.
Exports are set to increase, with the company guiding for Rs 280 crore in generics formulations turnover in FY25 and targeting Rs 350 crore by year-end (Source: freepik)
Delius Pharmaceuticals Pvt Ltd posted a 672.50% year-on-year revenue increase in Q1 FY25, driven by sales in its cephalosporin and ampicillin beta-lactam branded generics portfolio, expansion in branded generics, and large-scale imports from China.
The company announced new leadership appointments: Sanjeev (ex-Apex Healthcare) will lead prescription-driven doctor engagement, Jay (ex-Ranbaxy, Sanofi, GSK, Dr. Reddy’s, Airtel) will manage pan-India doctor relations, and Ajeet (ex-Glenmark, Ipca, Indoco) will focus on operational efficiency.
Delius signed an agreement with Chinese API supplier Apeloa for 100 tons of 6-APA and ester supply, ensuring raw material availability and cost efficiencies.
Chairman Digvijay Shrivastawa said the company aims to strengthen all channels, including distributors, hospitals, chemists, and retail counters, with a focus on the antibiotics segment.
Exports are set to increase, with the company guiding for Rs 280 crore in generics formulations turnover in FY25 and targeting Rs 350 crore by year-end. A rs 70 crore bank-supported investment in a new beta and non-beta manufacturing plant is planned to scale capacity and R&D.
Industry observers note that with the growth strategy, expanded leadership, and secured supply chain, Delius aims to compete with established pharma companies in the generics market.
Empower your business. Get practical tips, market insights, and growth strategies delivered to your inbox
By continuing you agree to our Privacy Policy & Terms & Conditions
